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Abstract
Introduction—Brain metastases (BM) are common in non-small-cell lung cancer (NSCLC). 
However, the baseline incidence and evolution of BM over time in oncogene-driven NSCLCs are 
seldom reported. In this study, we evaluated the frequency of BM in patients with epidermal 
growth factor receptor (EGFR)-mutated or anaplastic lymphoma kinase (ALK)-rearranged 
NSCLC.
Methods—The presence of BM, clinicopathologic data, and tumor genotype were retrospectively 
compiled and analyzed from a cohort of 381 patients.
Results—We identified 86 EGFR-mutated (90.7% with metastatic disease; 85.9% received an 
EGFR inhibitor) and 23 ALK-rearranged (91.3% with metastatic disease; 85.7% received an ALK 
inhibitor) NSCLCs. BM were present in 24.4% of EGFR-mutated and 23.8% of ALK-rearranged 
NSCLCs at the time of diagnosis of advanced disease. This study did not demonstrate a difference 
in the cumulative incidence of BM over time between the two cohorts (EGFR/ALK cohort 
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competing risk regression [CRR] coefficient of 0.78 [95% CI 0.44–1.39], p=0.41). In still living 
patients with advanced EGFR-mutated NSCLC, 34.2% had BM at 1 year, 38.4% at 2 years, 46.7% 
at 3 years, 48.7% at 4 years, and 52.9% at 5 years. In still living patients with advanced ALK-
rearranged NSCLC, 23.8% had BM at 1 year, 45.5% at 2 years, and 58.4% at 3 years.
Conclusions—BM are frequent in advanced EGFR-mutated or ALK-rearranged NSCLCs, with 
an estimated >45% of patients with CNS involvement by three years of survival with the use of 
targeted therapies. These data point toward the CNS as an important unmet clinical need in the 
evolving schema for personalized care in NSCLC.
Keywords
lung cancer; NSCLC; brain metastases; EGFR; ALK; mutation; rearrangement; central nervous 
system; CNS
INTRODUCTION
Non-small-cell lung cancer (NSCLC) is the leading cause of brain metastases (BM) (1). 
Amongst those with recurrent/advanced NSCLC, BM are a common culprit for cancer-
related morbidity and mortality. The incidence of BM in NSCLC has been reported as >20% 
at diagnosis, with a significant proportion of patients developing BM over the course of their 
disease (2, 3). Recent reports also demonstrate an increase in the documented incidence of 
BM in NSCLC, likely as a consequence of prolonged survival with newer therapies coupled 
with improvements in neuroimaging modalities (4).
Far less is known about the baseline incidence and subsequent evolution of BM in the subset 
of patients with oncogene-driven tumors, i.e. epidermal growth factor (EGFR)-mutated or 
anaplastic lymphoma kinase (ALK)-rearranged NSCLC (5, 6). Given the growing emphasis 
on molecular profiling and use of targeted therapeutics (7), this is a critical population. An 
improved understanding of the incidence and evolution of BM in these cases is therefore an 
area of ongoing need.
Herein, we report the baseline and cumulative incidence of BM in patients with EGFR-
mutated or ALK-rearranged advanced NSCLC.
MATERIALS AND METHODS
Cohort selection
Patients seen at Beth Israel Deaconess Medical Center (BIDMC) with a diagnosis of 
NSCLC and whose tumors were genotyped were identified through an ongoing Institutional 
Review Board-approved study (8,9), with a data cutoff of December 19, 2012 for patient 
inclusion and June 24, 2014 for outcomes.
Tumor genotype
EGFR mutation analysis (exons 18 to 21) was performed using standard sequencing 
techniques, and ALK rearrangement was analyzed using the Vysis ALK break-apart 
fluorescence in situ hybridization (FISH) probe (8).
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Data collection and detection of BM
Data was collected by retrospective chart review and managed using REDCap electronic 
data capture tools hosted at BIDMC. All patients with advanced NSCLC (stage IV/recurrent 
disease) had baseline CNS evaluation with either computed tomography (CT) or magnetic 
resonance imaging (MRI). Subsequent CNS assessment was performed at the discretion of 
the treating physicians. BM were diagnosed either radiographically or pathologically (tumor 
resection/biopsy or malignant CSF cytology).
Statistical methods
Fisher’s exact test was used to compare categorical variables, and Wilcoxon rank test was 
used for continuous variables. All p-values reported are two-sided, and tests were conducted 
at the 0.05-level. Time to BM was defined as the time from diagnosis to date of detected 
BM, and cumulative incidence curves were fitted and compared using the methodologies of 
Fine and Gray (10), adjusting for death as a competing risk. Patients not experiencing BM or 
death by the time of data cutoff were censored at their last date of follow-up. Overall 
survival (OS) was analyzed using the Kaplan–Meier method. Statistical analyses and curves 
were performed with the cmprsk package in R Statistical Programming Language.
RESULTS
Patient and tumor characteristics
The complete cohort comprised 381 patients, with a median age at diagnosis of 65 years. 
Self-reported racial groups were 75.9% white, 13.1% Asian, 6.5% black, and 4.4% other. 
27.8% of patients were never smokers, 54.9% were former smokers, and 17.3% current 
smokers. At the time of initial entry into the cohort, 73.8% had stage IV/recurrent disease, 
and 86.1% had adenocarcinoma histology. EGFR and ALK analysis was successful in 94.2% 
(359/381) and 91.6% (252/275) of tested samples, respectively (8). The overall frequency of 
EGFR mutations and ALK FISH positivity was 23.9% (86/359) and 9.1% (23/252), 
respectively. Abnormalities in EGFR and ALK were mutually exclusive in all genotyped 
tumors.
Characteristics of EGFR-mutated or ALK-rearranged NSCLCs
The EGFR-mutated cohort was comprised of more women; however, both cohorts 
predominantly involved patients with no tobacco history, advanced disease, and 
adenocarcinoma histology (Table 1). 85.9% (67/86) of patients with EGFR-mutated 
NSCLCs received an EGFR tyrosine kinase inhibitor (TKI) -gefitinib, erlotinib, or 
dacomitinib – at some point in their treatment course. 85.7% (18/23) of patients with ALK-
rearranged NSCLCs received the ALK TKI, crizotinib (Table 1). The median follow-up for 
patients with EGFR-mutated and ALK-rearranged NSCLC was 45.2 and 36.4 months, 
respectively.
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BM in EGFR-mutated NSCLC
24.4% (19/78) of the patients with EGFR-mutated NSCLC had BM at initial evaluation. The 
cumulative incidence of post-diagnosis BM increased over time (Figure 1A): 34.2% at 1 
year, 38.4% at 2 years, 46.7% at 3 years, 48.7% at 4 years, and 52.9% at 5 years.
BM in ALK-rearranged NSCLC
23.8% (5/21) of the patients with ALK-rearranged NSCLC had BM at initial evaluation. The 
cumulative incidence of post-diagnosis BM increased over time (Figure 1A): 23.8% at 1 
year, 45.5% at 2 years, and 58.4% at 3 years. At the time of data cutoff, none of the patients 
with ALK-rearranged NSCLC had reached beyond the 4-year survival mark.
Differences in BM between EGFR-mutated and ALK-rearranged NSCLC
No statistically significant difference was observed in the baseline and subsequent incidence 
of BM with EGFR-mutated versus ALK-rearranged tumors (Figure 1A). Additionally, this 
study did not demonstrate a difference in the cumulative incidence of BM over time between 
the two cohorts (EGFR/ALK cohort CRR coefficient of 0.78 [95% CI 0.44–1.39], p=0.41). 
However, since the ALK-rearranged cohort had fewer patients and less follow-up time than 
the EGFR-mutated group, it is unknown if differences may have evolved during subsequent 
follow-up.
Overall survival
Survival curves are depicted in Figure 1B. Amongst the 78 patients with an EGFR mutation, 
the median OS was 34.4 months (95% CI 28.1–49.1). Median OS amongst the 21 patients 
with an ALK rearrangement was 38.3 months (95% CI 22.3-NA).
DISCUSSION
We retrospectively evaluated a cohort of patients with EGFR-mutated or ALK-rearranged 
advanced NSCLC. BM were common, with nearly 25% of patients with BM at initial 
diagnosis and approximately half of patients with BM by 3 years in the setting of precision 
therapies. Limitations of this study include its retrospective nature and the lack of a 
standardized protocol for CNS assessment. Nevertheless, to our knowledge, this is the 
largest study to assess the baseline incidence and subsequent evolution of BM in these 
molecularly-defined groups.
The clinical course of patients with these oncogene-driven NSCLCs is an area of ongoing 
investigation. The University of Colorado evaluated patterns of metastatic spread in 209 
patients with treatment-naïve EGFR-mutated, KRAS-mutated, ALK-rearranged, and EGFR/
KRAS/ALK-unaffected advanced NSCLC (11). Similar to our findings, BM was present at 
diagnosis in 23% and 24% of EGFR-mutated and ALK-rearranged patients, respectively 
(11). In one retrospective study, BM were reported in 8% (5 of 62) EGFR-mutated patients 
at diagnosis, with an additional 24% diagnosed with BM at follow-up (12). The overall 
incidence of BM in this cohort was 32%, and time to BM and post-BM survival were 20.8 
and 12.1 months, respectively (12). One other study of 93 patients with NSCLC and BM 
undergoing mutational analysis for EGFR found 49% (20 of 41) of EGFR-mutated NSCLCs 
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with synchronous BM at the time of initial diagnosis (13). Time to progression in the brain 
was non-significantly longer in EGFR-mutated NSCLCs as compared to those with wild-
type EGFR (13). The prevalence of BM in the published trials of TKIs in advanced NSCLC 
to-date is similarly impressive, with more than 10% of patients in the first line trials of 
EGFR TKIs (5) and 35% of patients in the second line trials of ALK TKIs (6) noted to have 
baseline asymptomatic BM.
As targeted therapies continue to improve outcomes for patients with molecularly-driven 
NSCLCs (5–7), the deterrence of BM has become an increasingly relevant therapeutic 
dilemma. Most available TKIs (gefitinib, erlotinib, and crizotinib) inefficiently cross the 
intact blood–brain barrier with cerebrospinal fluid-to-plasma ratios as low as 0.01 to 0.003 
detected in patients (14). Even so, it seems that their use can still alter the natural history of 
BM. In one report of 155 EGFR-mutated NSCLCs, the 12- and 24-month cumulative risk of 
CNS progression was 6% and 21% in the group initially treated with an EGFR TKI, as 
compared to 19% and 32% in the group receiving first line chemotherapy; a hazard ratio of 
0.56 (95% CI 0.34–0.94) was noted for CNS progression, favoring upfront EGFR TKI over 
chemotherapy (15). Although a similar comparison has not been performed for ALK-
rearranged NSCLC, crizotinib and other ALK TKIs (such as ceritinib and alectinib) can also 
positively influence CNS disease (7). Ceritinib and alectinib have reported CNS activity in 
patients with ALK-rearranged NSCLC that are naïve or resistant to crizotinib therapy (7). 
Since our group’s cohort and those of others (5–7) predominantly studied patients that 
received TKIs, it is tempting to postulate that the cumulative incidence of BM may have 
been even higher in patients treated with chemotherapy alone. Contemporary clinical trials 
of novel EGFR and ALK TKIs now mandate baseline CNS imaging at study entry for all 
patients and have started to stratify patients based on presence/absence of BM. Such efforts 
will hopefully define prospectively whether CNS and systemic sites differ in patterns of 
response/progression in the setting of TKI use (7). Moreover, these studies will aid in 
delineating strategies for optimal surveillance for and detection of BM early in the course of 
CNS progression, for which there is currently no established standard.
Acquired resistance to targeted therapies remains a key limitation in achieving a durable 
benefit. Even as the major mechanisms of acquired systemic resistance are known to result 
from resistant tyrosine kinase mutations and activation of bypass pathways (7), the 
mechanisms that explain CNS progression remain largely unknown. As reported here and 
elsewhere (5–7, 10–12), the CNS is amongst the most frequent sites of disease progression 
in patients whose systemic disease is otherwise being successfully controlled with TKIs. The 
optimal management of BM in oncogene-driven NSCLCs remains uncertain, and the use of 
whole brain or stereotactic radiotherapy remains a cornerstone of care (16).
In conclusion, this retrospective study demonstrates the high initial incidence (nearly 25%) 
and subsequent prevalence of BM in patients with advanced EGFR-mutated or ALK-
rearranged NSCLCs treated with TKIs. Given their frequency in tumors with these driver 
mutations, increased inclusion of patients with BM in innovative trials of targeted therapies 
will be critical in defining their full potential and facilitating their application in real-world 
practice. Developing optimal strategies for the prevention and management of CNS disease 
has become one of the foremost clinical questions in the care of these patients. Future 
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studies should address the role of TKIs with improved CNS penetration, the use of less toxic 
radiotherapy techniques for BM, and the need to better understand the molecular 
underpinnings of malignant CNS disease.
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HIGHLIGHTS
- Brain metastases are frequent in ALK rearranged lung cancers
- Brain metastases are frequent in EGFR mutated lung cancers
- ~25% of patients at diagnosis and half at 3-years of survival have brain 
metastases
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Figure 1. 
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Table 1
Baseline characteristics of patients and tumors with EGFR-mutated and ALK-rearranged NSCLC.
Tumor genotype
EGFR-mutated
(n=86)
ALK-rearranged
(n=23) p-value
Age at time of biopsy
Median (range) 65 (33–90) 56 (29–80) <0.0001*
Women n (%) 64 (74.4) 11 (47.8) 0.0218
Race n (%)
 White 50 (58.1) 15 (65.2) 0.6357
 Asian 31 (36.1) 4 (17.4)
 Black 4 (4.6) 0 (0)
 Other 1 (1.2) 4 (17.4)
Smoking status n (%)
 Current smoker 4 (4.65) 1 (4.3) 0.4909
 Former smoker 37 (43.0) 8 (34.8)
 Never smoker 45 (52.3) 14 (60.9)
Stage n (%)
 I–III 8 (9.3) 2 (8.7) 1.0000
 IV/recurrent 78 (90.7) 21 (91.3)
Histology n (%)
 Adenocarcinoma 84 (97.7) 21 (91.3) 0.1952
 Squamous cell carcinoma 0 (0) 1 (4.3)
 NSCLC (NOS) 2 (2.3) 1 (4.3)
Use of precision TKI n (%)
 When stage IV/recurrent 67 (85.9) 18 (85.7) 1.0000
Baseline brain metastases n (%)
 When stage IV/recurrent 19 (24.4) 5 (23.8) 1.0000
NSCLC = non-small-cell lung cancer; NOS = not otherwise specified; TKI = tyrosine kinase inhibitor.
*Wilcoxon-Rank Sum test
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